The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.

Launched by LO.LI.PHARMA S.R.L · Feb 28, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating whether a dietary supplement made from a natural compound called EGCG, along with vitamins B12 and folic acid, can help prevent the persistence of HPV (human papillomavirus) infections, particularly in women. HPV is a common virus that can affect the cervix, and this study aims to see if these supplements can support the body in fighting off the infection more effectively.

To participate in this trial, women must be between the ages of 18 and 65 and have tested positive for high-risk HPV. However, those with a specific type of cervical cell change known as HSIL (high-grade squamous intraepithelial lesions) cannot join the study. If eligible, participants can expect to receive the dietary supplement and will be monitored for its effects on their HPV infection. This is an important opportunity to explore potential new treatments for HPV and help improve women's health.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • HR-HPV DNA test positivity
• Exclusion Criteria:
• • No HSIL